Global Point of Care Molecular Diagnostics Market
Global Point of Care Molecular Diagnostics Market

Point of Care Molecular Diagnostics Comprehensive Study by Type (Rt-Pcr, Inaat, Industry Segmentation, Physician Offices, Hospital Emergency Departments & Intensive Care Units, Research Institutes, Channel (Direct Sales, Distributor) Segmentation, Section 8: 400 USD??Trend (2019-2024), Section 9: 300 USD??Product Type Detail, Section 10: 700 USD??Downstream Consumer, Section 11: 200 USD??Cost Structure, Section 12: 500 USD??Conclusion), Product (Assays & Kits, Instruments/Analysers, Services & Software), End-Use (Physician Offices, Health Department Clinics, Pharmacy Clinics, Others), Tests (RT-PCR, INAAT, Others) Players and Region - Global Market Outlook to 2026

Point of Care Molecular Diagnostics Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Dec 2021 Edition 225 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Point of Care Molecular Diagnostics Market Overview:
Point of Care Molecular allows a physician to make a diagnosis or rule out a diagnosis and treat a patient while they are still in the clinic. Furthermore, as compared to rapid antigen detection tests, molecular assays have shown better sensitivity, removing the need for secondary confirmation of negative results and leading in much more appropriate antibiotic administration, including the avoidance of antibiotic use for viral infections.

Growth Drivers
  • Microfluidics and Other Instrumentation Technologies That Allow for the Creation of Low-Cost Platforms and Tests

Roadblocks
  • Time-Consuming and Stringent Government Regulations and Policies

Opportunities
  • In Resource-Constrained Environments, Molecular POCT is Becoming Increasingly Beneficial

Challenges
  • Direct Interaction With a Patient During Specimen Collection Poses the Highest Danger


Competitive Landscape:
Competitive Landscape and The demand for POC Molecular Diagnostics is increasing by each passing day . The businesses in this industry facing major competition on a global scale with leading players of the market who hold a major market share. The Leading Players are engaging in organic and non-organic strategic global expansion to maintain their Market Position.
Some of the key players profiled in the report are Roche (Switzerland), Abbott Laboratories (United States), Biomerieux (France), Danaher (United States), Roche diagnostics (Switzerland), Meridian biosciences (United States), Quidel (United States), Sanofi (France), Merck (United States) and Johnson and Johnson (United States). Additionally, following companies can also be profiled that are part of our coverage like Cardea (United States), Inflammatix (United States) and Sherlock Biosciences (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Point of Care Molecular Diagnostics market by 2026. Considering Market by Product, the sub-segment i.e. Assays & Kits will boost the Point of Care Molecular Diagnostics market. Considering Market by End-Use, the sub-segment i.e. Physician Offices will boost the Point of Care Molecular Diagnostics market. Considering Market by Tests, the sub-segment i.e. RT-PCR will boost the Point of Care Molecular Diagnostics market.

Latest Market Insights:
In March 2021 Roche Released a Statement Stating the Acquisition of Genmark. The ePlex technology from GenMark provides clinicians with quick and actionable findings, allowing them to pinpoint the source of infection and the most effective therapy, potentially saving lives and reducing healthcare costs. Roche's diagnostic portfolio has been enhanced by the integration of GenMark's unique multiplex technology, which addresses a wide range of infectious disease testing needs, including respiratory and bloodstream infections.

What Can be Explored with the Point of Care Molecular Diagnostics Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Point of Care Molecular Diagnostics Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Point of Care Molecular Diagnostics
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Point of Care Molecular Diagnostics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Point of Care Molecular Diagnostics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Government Regulatory and Research Organizations, Healthcare Organization, Pharmaceutical Companies and End-Use Industries.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Point of Care Molecular Diagnostics Market?
The Point of Care Molecular Diagnostics market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Point of Care Molecular Diagnostics Market?
Top performing companies in the Global Point of Care Molecular Diagnostics market are Roche (Switzerland), Abbott Laboratories (United States), Biomerieux (France), Danaher (United States), Roche diagnostics (Switzerland), Meridian biosciences (United States), Quidel (United States), Sanofi (France), Merck (United States) and Johnson and Johnson (United States), to name a few.

3. What trending factors would impact Point of Care Molecular Diagnostics Market growth most?
"Rise in CLIA-Waived Molecular POC Tests" is seen as one of major influencing trends for Point of Care Molecular Diagnostics Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Type
  • Rt-Pcr
  • Inaat
  • Industry Segmentation
  • Physician Offices
  • Hospital Emergency Departments & Intensive Care Units
  • Research Institutes
  • Channel (Direct Sales, Distributor) Segmentation
  • Section 8: 400 USD??Trend (2019-2024)
  • Section 9: 300 USD??Product Type Detail
  • Section 10: 700 USD??Downstream Consumer
  • Section 11: 200 USD??Cost Structure
  • Section 12: 500 USD??Conclusion
By Product
  • Assays & Kits
  • Instruments/Analysers
  • Services & Software

By End-Use
  • Physician Offices
  • Health Department Clinics
  • Pharmacy Clinics
  • Others

By Tests
  • RT-PCR
  • INAAT
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Microfluidics and Other Instrumentation Technologies That Allow for the Creation of Low-Cost Platforms and Tests
    • 3.3. Market Challenges
      • 3.3.1. Direct Interaction With a Patient During Specimen Collection Poses the Highest Danger
    • 3.4. Market Trends
      • 3.4.1. Rise in CLIA-Waived Molecular POC Tests
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Point of Care Molecular Diagnostics, by Type, Product, End-Use, Tests and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Point of Care Molecular Diagnostics (Value)
      • 5.2.1. Global Point of Care Molecular Diagnostics by: Type (Value)
        • 5.2.1.1. Rt-Pcr
        • 5.2.1.2. Inaat
        • 5.2.1.3. Industry Segmentation
        • 5.2.1.4. Physician Offices
        • 5.2.1.5. Hospital Emergency Departments & Intensive Care Units
        • 5.2.1.6. Research Institutes
        • 5.2.1.7. Channel (Direct Sales, Distributor) Segmentation
        • 5.2.1.8. Section 8: 400 USD??Trend (2019-2024)
        • 5.2.1.9. Section 9: 300 USD??Product Type Detail
        • 5.2.1.10. Section 10: 700 USD??Downstream Consumer
        • 5.2.1.11. Section 11: 200 USD??Cost Structure
        • 5.2.1.12. Section 12: 500 USD??Conclusion
      • 5.2.2. Global Point of Care Molecular Diagnostics by: Product (Value)
        • 5.2.2.1. Assays & Kits
        • 5.2.2.2. Instruments/Analysers
        • 5.2.2.3. Services & Software
      • 5.2.3. Global Point of Care Molecular Diagnostics by: End-Use (Value)
        • 5.2.3.1. Physician Offices
        • 5.2.3.2. Health Department Clinics
        • 5.2.3.3. Pharmacy Clinics
        • 5.2.3.4. Others
      • 5.2.4. Global Point of Care Molecular Diagnostics by: Tests (Value)
        • 5.2.4.1. RT-PCR
        • 5.2.4.2. INAAT
        • 5.2.4.3. Others
      • 5.2.5. Global Point of Care Molecular Diagnostics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Point of Care Molecular Diagnostics (Price)
      • 5.3.1. Global Point of Care Molecular Diagnostics by: Type (Price)
  • 6. Point of Care Molecular Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biomerieux (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Danaher (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Roche diagnostics (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Meridian biosciences (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Quidel (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson and Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Point of Care Molecular Diagnostics Sale, by Type, Product, End-Use, Tests and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Point of Care Molecular Diagnostics (Value)
      • 7.2.1. Global Point of Care Molecular Diagnostics by: Type (Value)
        • 7.2.1.1. Rt-Pcr
        • 7.2.1.2. Inaat
        • 7.2.1.3. Industry Segmentation
        • 7.2.1.4. Physician Offices
        • 7.2.1.5. Hospital Emergency Departments & Intensive Care Units
        • 7.2.1.6. Research Institutes
        • 7.2.1.7. Channel (Direct Sales, Distributor) Segmentation
        • 7.2.1.8. Section 8: 400 USD??Trend (2019-2024)
        • 7.2.1.9. Section 9: 300 USD??Product Type Detail
        • 7.2.1.10. Section 10: 700 USD??Downstream Consumer
        • 7.2.1.11. Section 11: 200 USD??Cost Structure
        • 7.2.1.12. Section 12: 500 USD??Conclusion
      • 7.2.2. Global Point of Care Molecular Diagnostics by: Product (Value)
        • 7.2.2.1. Assays & Kits
        • 7.2.2.2. Instruments/Analysers
        • 7.2.2.3. Services & Software
      • 7.2.3. Global Point of Care Molecular Diagnostics by: End-Use (Value)
        • 7.2.3.1. Physician Offices
        • 7.2.3.2. Health Department Clinics
        • 7.2.3.3. Pharmacy Clinics
        • 7.2.3.4. Others
      • 7.2.4. Global Point of Care Molecular Diagnostics by: Tests (Value)
        • 7.2.4.1. RT-PCR
        • 7.2.4.2. INAAT
        • 7.2.4.3. Others
      • 7.2.5. Global Point of Care Molecular Diagnostics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Point of Care Molecular Diagnostics (Price)
      • 7.3.1. Global Point of Care Molecular Diagnostics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Point of Care Molecular Diagnostics: by Type(USD Million)
  • Table 2. Point of Care Molecular Diagnostics Rt-Pcr , by Region USD Million (2015-2020)
  • Table 3. Point of Care Molecular Diagnostics Inaat , by Region USD Million (2015-2020)
  • Table 4. Point of Care Molecular Diagnostics Industry Segmentation , by Region USD Million (2015-2020)
  • Table 5. Point of Care Molecular Diagnostics Physician Offices , by Region USD Million (2015-2020)
  • Table 6. Point of Care Molecular Diagnostics Hospital Emergency Departments & Intensive Care Units , by Region USD Million (2015-2020)
  • Table 7. Point of Care Molecular Diagnostics Research Institutes , by Region USD Million (2015-2020)
  • Table 8. Point of Care Molecular Diagnostics Channel (Direct Sales, Distributor) Segmentation , by Region USD Million (2015-2020)
  • Table 9. Point of Care Molecular Diagnostics Section 8: 400 USD??Trend (2019-2024) , by Region USD Million (2015-2020)
  • Table 10. Point of Care Molecular Diagnostics Section 9: 300 USD??Product Type Detail , by Region USD Million (2015-2020)
  • Table 11. Point of Care Molecular Diagnostics Section 10: 700 USD??Downstream Consumer , by Region USD Million (2015-2020)
  • Table 12. Point of Care Molecular Diagnostics Section 11: 200 USD??Cost Structure , by Region USD Million (2015-2020)
  • Table 13. Point of Care Molecular Diagnostics Section 12: 500 USD??Conclusion , by Region USD Million (2015-2020)
  • Table 14. Point of Care Molecular Diagnostics: by Product(USD Million)
  • Table 15. Point of Care Molecular Diagnostics Assays & Kits , by Region USD Million (2015-2020)
  • Table 16. Point of Care Molecular Diagnostics Instruments/Analysers , by Region USD Million (2015-2020)
  • Table 17. Point of Care Molecular Diagnostics Services & Software , by Region USD Million (2015-2020)
  • Table 18. Point of Care Molecular Diagnostics: by End-Use(USD Million)
  • Table 19. Point of Care Molecular Diagnostics Physician Offices , by Region USD Million (2015-2020)
  • Table 20. Point of Care Molecular Diagnostics Health Department Clinics , by Region USD Million (2015-2020)
  • Table 21. Point of Care Molecular Diagnostics Pharmacy Clinics , by Region USD Million (2015-2020)
  • Table 22. Point of Care Molecular Diagnostics Others , by Region USD Million (2015-2020)
  • Table 23. Point of Care Molecular Diagnostics: by Tests(USD Million)
  • Table 24. Point of Care Molecular Diagnostics RT-PCR , by Region USD Million (2015-2020)
  • Table 25. Point of Care Molecular Diagnostics INAAT , by Region USD Million (2015-2020)
  • Table 26. Point of Care Molecular Diagnostics Others , by Region USD Million (2015-2020)
  • Table 27. South America Point of Care Molecular Diagnostics, by Country USD Million (2015-2020)
  • Table 28. South America Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 29. South America Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 30. South America Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 31. South America Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 32. Brazil Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 33. Brazil Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 34. Brazil Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 35. Brazil Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 36. Argentina Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 37. Argentina Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 38. Argentina Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 39. Argentina Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 40. Rest of South America Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 41. Rest of South America Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 42. Rest of South America Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 43. Rest of South America Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 44. Asia Pacific Point of Care Molecular Diagnostics, by Country USD Million (2015-2020)
  • Table 45. Asia Pacific Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 46. Asia Pacific Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 47. Asia Pacific Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 48. Asia Pacific Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 49. China Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 50. China Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 51. China Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 52. China Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 53. Japan Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 54. Japan Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 55. Japan Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 56. Japan Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 57. India Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 58. India Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 59. India Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 60. India Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 61. South Korea Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 62. South Korea Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 63. South Korea Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 64. South Korea Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 65. Australia Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 66. Australia Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 67. Australia Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 68. Australia Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 73. Europe Point of Care Molecular Diagnostics, by Country USD Million (2015-2020)
  • Table 74. Europe Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 75. Europe Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 76. Europe Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 77. Europe Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 78. Germany Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 79. Germany Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 80. Germany Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 81. Germany Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 82. France Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 83. France Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 84. France Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 85. France Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 86. Italy Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 87. Italy Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 88. Italy Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 89. Italy Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 90. United Kingdom Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 91. United Kingdom Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 92. United Kingdom Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 93. United Kingdom Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 94. Netherlands Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 95. Netherlands Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 96. Netherlands Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 97. Netherlands Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 98. Rest of Europe Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 99. Rest of Europe Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 100. Rest of Europe Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 101. Rest of Europe Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 102. MEA Point of Care Molecular Diagnostics, by Country USD Million (2015-2020)
  • Table 103. MEA Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 104. MEA Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 105. MEA Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 106. MEA Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 107. Middle East Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 108. Middle East Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 109. Middle East Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 110. Middle East Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 111. Africa Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 112. Africa Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 113. Africa Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 114. Africa Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 115. North America Point of Care Molecular Diagnostics, by Country USD Million (2015-2020)
  • Table 116. North America Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 117. North America Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 118. North America Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 119. North America Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 120. United States Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 121. United States Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 122. United States Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 123. United States Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 124. Canada Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 125. Canada Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 126. Canada Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 127. Canada Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 128. Mexico Point of Care Molecular Diagnostics, by Type USD Million (2015-2020)
  • Table 129. Mexico Point of Care Molecular Diagnostics, by Product USD Million (2015-2020)
  • Table 130. Mexico Point of Care Molecular Diagnostics, by End-Use USD Million (2015-2020)
  • Table 131. Mexico Point of Care Molecular Diagnostics, by Tests USD Million (2015-2020)
  • Table 132. Point of Care Molecular Diagnostics: by Type(USD/Units)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Point of Care Molecular Diagnostics: by Type(USD Million)
  • Table 144. Point of Care Molecular Diagnostics Rt-Pcr , by Region USD Million (2021-2026)
  • Table 145. Point of Care Molecular Diagnostics Inaat , by Region USD Million (2021-2026)
  • Table 146. Point of Care Molecular Diagnostics Industry Segmentation , by Region USD Million (2021-2026)
  • Table 147. Point of Care Molecular Diagnostics Physician Offices , by Region USD Million (2021-2026)
  • Table 148. Point of Care Molecular Diagnostics Hospital Emergency Departments & Intensive Care Units , by Region USD Million (2021-2026)
  • Table 149. Point of Care Molecular Diagnostics Research Institutes , by Region USD Million (2021-2026)
  • Table 150. Point of Care Molecular Diagnostics Channel (Direct Sales, Distributor) Segmentation , by Region USD Million (2021-2026)
  • Table 151. Point of Care Molecular Diagnostics Section 8: 400 USD??Trend (2019-2024) , by Region USD Million (2021-2026)
  • Table 152. Point of Care Molecular Diagnostics Section 9: 300 USD??Product Type Detail , by Region USD Million (2021-2026)
  • Table 153. Point of Care Molecular Diagnostics Section 10: 700 USD??Downstream Consumer , by Region USD Million (2021-2026)
  • Table 154. Point of Care Molecular Diagnostics Section 11: 200 USD??Cost Structure , by Region USD Million (2021-2026)
  • Table 155. Point of Care Molecular Diagnostics Section 12: 500 USD??Conclusion , by Region USD Million (2021-2026)
  • Table 156. Point of Care Molecular Diagnostics: by Product(USD Million)
  • Table 157. Point of Care Molecular Diagnostics Assays & Kits , by Region USD Million (2021-2026)
  • Table 158. Point of Care Molecular Diagnostics Instruments/Analysers , by Region USD Million (2021-2026)
  • Table 159. Point of Care Molecular Diagnostics Services & Software , by Region USD Million (2021-2026)
  • Table 160. Point of Care Molecular Diagnostics: by End-Use(USD Million)
  • Table 161. Point of Care Molecular Diagnostics Physician Offices , by Region USD Million (2021-2026)
  • Table 162. Point of Care Molecular Diagnostics Health Department Clinics , by Region USD Million (2021-2026)
  • Table 163. Point of Care Molecular Diagnostics Pharmacy Clinics , by Region USD Million (2021-2026)
  • Table 164. Point of Care Molecular Diagnostics Others , by Region USD Million (2021-2026)
  • Table 165. Point of Care Molecular Diagnostics: by Tests(USD Million)
  • Table 166. Point of Care Molecular Diagnostics RT-PCR , by Region USD Million (2021-2026)
  • Table 167. Point of Care Molecular Diagnostics INAAT , by Region USD Million (2021-2026)
  • Table 168. Point of Care Molecular Diagnostics Others , by Region USD Million (2021-2026)
  • Table 169. South America Point of Care Molecular Diagnostics, by Country USD Million (2021-2026)
  • Table 170. South America Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 171. South America Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 172. South America Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 173. South America Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 174. Brazil Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 175. Brazil Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 176. Brazil Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 177. Brazil Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 178. Argentina Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 179. Argentina Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 180. Argentina Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 181. Argentina Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 182. Rest of South America Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 183. Rest of South America Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 184. Rest of South America Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 185. Rest of South America Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 186. Asia Pacific Point of Care Molecular Diagnostics, by Country USD Million (2021-2026)
  • Table 187. Asia Pacific Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 188. Asia Pacific Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 189. Asia Pacific Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 190. Asia Pacific Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 191. China Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 192. China Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 193. China Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 194. China Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 195. Japan Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 196. Japan Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 197. Japan Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 198. Japan Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 199. India Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 200. India Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 201. India Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 202. India Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 203. South Korea Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 204. South Korea Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 205. South Korea Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 206. South Korea Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 207. Australia Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 208. Australia Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 209. Australia Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 210. Australia Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 211. Rest of Asia-Pacific Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 212. Rest of Asia-Pacific Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 213. Rest of Asia-Pacific Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 214. Rest of Asia-Pacific Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 215. Europe Point of Care Molecular Diagnostics, by Country USD Million (2021-2026)
  • Table 216. Europe Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 217. Europe Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 218. Europe Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 219. Europe Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 220. Germany Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 221. Germany Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 222. Germany Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 223. Germany Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 224. France Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 225. France Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 226. France Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 227. France Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 228. Italy Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 229. Italy Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 230. Italy Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 231. Italy Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 232. United Kingdom Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 233. United Kingdom Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 234. United Kingdom Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 235. United Kingdom Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 236. Netherlands Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 237. Netherlands Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 238. Netherlands Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 239. Netherlands Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 240. Rest of Europe Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 241. Rest of Europe Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 242. Rest of Europe Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 243. Rest of Europe Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 244. MEA Point of Care Molecular Diagnostics, by Country USD Million (2021-2026)
  • Table 245. MEA Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 246. MEA Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 247. MEA Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 248. MEA Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 249. Middle East Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 250. Middle East Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 251. Middle East Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 252. Middle East Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 253. Africa Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 254. Africa Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 255. Africa Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 256. Africa Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 257. North America Point of Care Molecular Diagnostics, by Country USD Million (2021-2026)
  • Table 258. North America Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 259. North America Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 260. North America Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 261. North America Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 262. United States Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 263. United States Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 264. United States Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 265. United States Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 266. Canada Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 267. Canada Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 268. Canada Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 269. Canada Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 270. Mexico Point of Care Molecular Diagnostics, by Type USD Million (2021-2026)
  • Table 271. Mexico Point of Care Molecular Diagnostics, by Product USD Million (2021-2026)
  • Table 272. Mexico Point of Care Molecular Diagnostics, by End-Use USD Million (2021-2026)
  • Table 273. Mexico Point of Care Molecular Diagnostics, by Tests USD Million (2021-2026)
  • Table 274. Point of Care Molecular Diagnostics: by Type(USD/Units)
  • Table 275. Research Programs/Design for This Report
  • Table 276. Key Data Information from Secondary Sources
  • Table 277. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Point of Care Molecular Diagnostics: by Type USD Million (2015-2020)
  • Figure 5. Global Point of Care Molecular Diagnostics: by Product USD Million (2015-2020)
  • Figure 6. Global Point of Care Molecular Diagnostics: by End-Use USD Million (2015-2020)
  • Figure 7. Global Point of Care Molecular Diagnostics: by Tests USD Million (2015-2020)
  • Figure 8. South America Point of Care Molecular Diagnostics Share (%), by Country
  • Figure 9. Asia Pacific Point of Care Molecular Diagnostics Share (%), by Country
  • Figure 10. Europe Point of Care Molecular Diagnostics Share (%), by Country
  • Figure 11. MEA Point of Care Molecular Diagnostics Share (%), by Country
  • Figure 12. North America Point of Care Molecular Diagnostics Share (%), by Country
  • Figure 13. Global Point of Care Molecular Diagnostics: by Type USD/Units (2015-2020)
  • Figure 14. Global Point of Care Molecular Diagnostics share by Players 2020 (%)
  • Figure 15. Global Point of Care Molecular Diagnostics share by Players (Top 3) 2020(%)
  • Figure 16. Global Point of Care Molecular Diagnostics share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Roche (Switzerland) Revenue: by Geography 2020
  • Figure 20. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 21. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 22. Biomerieux (France) Revenue, Net Income and Gross profit
  • Figure 23. Biomerieux (France) Revenue: by Geography 2020
  • Figure 24. Danaher (United States) Revenue, Net Income and Gross profit
  • Figure 25. Danaher (United States) Revenue: by Geography 2020
  • Figure 26. Roche diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Roche diagnostics (Switzerland) Revenue: by Geography 2020
  • Figure 28. Meridian biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 29. Meridian biosciences (United States) Revenue: by Geography 2020
  • Figure 30. Quidel (United States) Revenue, Net Income and Gross profit
  • Figure 31. Quidel (United States) Revenue: by Geography 2020
  • Figure 32. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 33. Sanofi (France) Revenue: by Geography 2020
  • Figure 34. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 35. Merck (United States) Revenue: by Geography 2020
  • Figure 36. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 37. Johnson and Johnson (United States) Revenue: by Geography 2020
  • Figure 38. Global Point of Care Molecular Diagnostics: by Type USD Million (2021-2026)
  • Figure 39. Global Point of Care Molecular Diagnostics: by Product USD Million (2021-2026)
  • Figure 40. Global Point of Care Molecular Diagnostics: by End-Use USD Million (2021-2026)
  • Figure 41. Global Point of Care Molecular Diagnostics: by Tests USD Million (2021-2026)
  • Figure 42. South America Point of Care Molecular Diagnostics Share (%), by Country
  • Figure 43. Asia Pacific Point of Care Molecular Diagnostics Share (%), by Country
  • Figure 44. Europe Point of Care Molecular Diagnostics Share (%), by Country
  • Figure 45. MEA Point of Care Molecular Diagnostics Share (%), by Country
  • Figure 46. North America Point of Care Molecular Diagnostics Share (%), by Country
  • Figure 47. Global Point of Care Molecular Diagnostics: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Roche (Switzerland)
  • Abbott Laboratories (United States)
  • Biomerieux (France)
  • Danaher (United States)
  • Roche diagnostics (Switzerland)
  • Meridian biosciences (United States)
  • Quidel (United States)
  • Sanofi (France)
  • Merck (United States)
  • Johnson and Johnson (United States)
Additional players considered in the study are as follows:
Cardea (United States) , Inflammatix (United States) , Sherlock Biosciences (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation